GM2A and neoplasm: Tumour incidence, which is the second highest comorbidity observed in this study (the other being weight loss) did not track with dose (11 incidents, 5 in spleen and 3 in liver; Figure 6B); and furthermore, the number of incidents in treated cohorts were comparable with numbers observed in vehicle-treated Gm2a−/− and Gm2a+/− disease-free cohorts (2 and 1 incident(s), respectively; Figure 6B).